CR2 and diffuse large B-cell lymphoma: IGHV3-23 gene usage was also reported in hairy cell leukemia [32], diffuse large B-cell lymphoma [33], after the immunization of malaria-naïve individuals with PfSPZ-CVac [34], HIV patients [35], and in CD21(low) B cells from WAS patients [36].